2026 Q1 -tulosraportti
85 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 t sittenGood interest in the closing auction. Wonder if they are still available for purchase tomorrow. We'll find out at 09:00. Good night and sleep well.
We are slowly but surely approaching the financial report, which will be published on August 20th. There has been no news of any problems of any kind, so my expectations are that they have followed guidance to the letter. The only news I think is worth mentioning is that Bioporto has started reaching out to future customers to inform them about KDIGO's recommendations regarding the NGAL test. And we have ourselves found out that hospitals within the EU have started writing on TED that the NGAL test must meet KDIGO's recommendations when they are to have NGAL tests in their treatment system or renew a contract. They must put it out to tender every 4th year, even if they intend to keep the system they already have. EU's tender rules. I guess we will hear more about KDIGO's recommendations.- ·3 päivää sittenInformation for the curious The summer holiday is over at BioPorto, and they have put their work clothes on again. The FDA demanded that there should be more patients, and therefore BioPorto has informed us that they need an additional 8 hospitals. Right now they have 12 hospitals. BioPorto is in full swing with the preliminary exercises to find the last 8 hospitals. I can see that, because on ClinicalTrials.gov it says 'Not yet recruiting'. If you click on information, you can see the conditions for being able to sign up for this research project. https://clinicaltrials.gov/study/NCT07751913There is soon a financial report on August 20th, it will be interesting to hear if everything goes according to plan.
- ·5.8. · MuokattuBioPorto – Presentation of H1 2026 results 20.08.2026, 14.00 tilmelding nødvendigt https://www.inderes.dk/videos/bioporto-praesentation-af-h1-2026-resultater
- ·4.8.Now the previously mentioned TED tender is over. As I have said, it is very complicated, so with good help from AI, I have arrived at the following It is Bioporto's NGAL test that the hospital in Romania has chosen. The value is 87.5 Danish kroner. the duration is over 4 years. (EU requirement that one may not enter into long-term agreements) For the sake of good order, the money will be transferred continuously. The entire agreement is stated below. The hospital has entered into a total framework agreement with a maximum framework value of 58,076,651.22 RON (corresponding to approximately 87.5 million Danish kroner).It is important to distinguish between the framework agreement's framework amount and the actual, implemented contracts: The framework agreement's maximum ceiling: The hospital can purchase for up to 58.07 million RON over the next 48 months. Implemented so far: The specific value of the contracts actually awarded and signed in this specific announcement amounts to 12,746,774.59 RON (approximately 19.2 million Danish kroner).The agreement is divided into sub-agreements (lots), where LOT-0001 (reagents for Abbott Alinity biochemistry and immunology) constitutes the absolute largest part with a maximum budgeted ceiling of 50,057,313.90 RON .(50,057,313.90 RON corresponds to approximately 75.6 million Danish kroner.) https://ted.europa.eu/en/search/result?publication-number=523285-2026&search-scope=ALL&scope=ALL&onlyLatestVersions=false&sortColumn=publication-number&sortOrder=DESC&page=1&simpleSearchRef=trueRolf Hansen We continue here on Bioporto What I meant by Bioporto being on the threshold of either a global success or a fiasco was that: When/if KDIGO finishes the mentioned documents, in my opinion, it cannot be avoided that Bioporto will achieve global success. But as long as KDIGO has not established with a finished document, where they have described in detail which treatment centers are affected by a strong recommendation and less strong recommendations, we cannot be entirely sure about the recommendations published currently. When I nevertheless wrote to you that it could also be a fiasco, it is because KDIGO has not finished rewriting the mentioned documents, and even though it seems very unlikely that they would suddenly change their mind, the risk is there until they are finished. I will compare it to what happened in Germany, that politicians for several months have publicly stated that they are working towards removing the subsidy for flower medicine, and this will only happen as of January 1, 2027. But like a thief in the night, the German parliament Bundestag decided that the subsidy should be removed as of July 30, 6 months earlier. For Stenocare's Weeco astrum 10/10, it has been an advantage, because doctors are now prescribing so many prescriptions for the oil that the pen has started to glow. In theory, the same could happen for Bioporto's NGAL test, but then it would be an inverse situation compared to Stenocare's situation. It is not normal for KDIGO to start by announcing which recommendations they will give to whom. They have made an exception this time to avoid bottleneck problems, because it is Bioporto's test they have used to come up with the recommendations below. I don't believe they will turn around on a dime and not come up with any recommendations after all, but as long as it's not set in stone, there will always be a minimal risk. But as I have written, I have bet money that there will be no negative surprises. Because during the consultation period, there was no evidence that the test did not work, only the opposite. In the same way, we also did not believe that politicians would remove the subsidy for flower medicine 6 months earlier than announced, and that it happened as described, we did not expect that to happen either. I must remember to write that the above is not a recommendation for what you should do. The red is the strongest recommendation, the blue moderate to strong recommendation, the yellow suggestion, the doctors' own assessment, the green no recommendation. https://kdigo.org/guidelines/
- ·1.8.I just discovered this from LinkedIn. I think this is relevant news because the treatment centers are in the process of complying with the various recommendations that KDIGO published in the spring. KDIGO's guideline update on biomarker use, and what the implementation actually looks like in a clinical laboratory. https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7487529288464760835&highlightedUpdateType=NETWORK_CONVERSATIONS&origin=EMAIL
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
85 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sittenGood interest in the closing auction. Wonder if they are still available for purchase tomorrow. We'll find out at 09:00. Good night and sleep well.We are slowly but surely approaching the financial report, which will be published on August 20th. There has been no news of any problems of any kind, so my expectations are that they have followed guidance to the letter. The only news I think is worth mentioning is that Bioporto has started reaching out to future customers to inform them about KDIGO's recommendations regarding the NGAL test. And we have ourselves found out that hospitals within the EU have started writing on TED that the NGAL test must meet KDIGO's recommendations when they are to have NGAL tests in their treatment system or renew a contract. They must put it out to tender every 4th year, even if they intend to keep the system they already have. EU's tender rules. I guess we will hear more about KDIGO's recommendations.
- ·3 päivää sittenInformation for the curious The summer holiday is over at BioPorto, and they have put their work clothes on again. The FDA demanded that there should be more patients, and therefore BioPorto has informed us that they need an additional 8 hospitals. Right now they have 12 hospitals. BioPorto is in full swing with the preliminary exercises to find the last 8 hospitals. I can see that, because on ClinicalTrials.gov it says 'Not yet recruiting'. If you click on information, you can see the conditions for being able to sign up for this research project. https://clinicaltrials.gov/study/NCT07751913There is soon a financial report on August 20th, it will be interesting to hear if everything goes according to plan.
- ·5.8. · MuokattuBioPorto – Presentation of H1 2026 results 20.08.2026, 14.00 tilmelding nødvendigt https://www.inderes.dk/videos/bioporto-praesentation-af-h1-2026-resultater
- ·4.8.Now the previously mentioned TED tender is over. As I have said, it is very complicated, so with good help from AI, I have arrived at the following It is Bioporto's NGAL test that the hospital in Romania has chosen. The value is 87.5 Danish kroner. the duration is over 4 years. (EU requirement that one may not enter into long-term agreements) For the sake of good order, the money will be transferred continuously. The entire agreement is stated below. The hospital has entered into a total framework agreement with a maximum framework value of 58,076,651.22 RON (corresponding to approximately 87.5 million Danish kroner).It is important to distinguish between the framework agreement's framework amount and the actual, implemented contracts: The framework agreement's maximum ceiling: The hospital can purchase for up to 58.07 million RON over the next 48 months. Implemented so far: The specific value of the contracts actually awarded and signed in this specific announcement amounts to 12,746,774.59 RON (approximately 19.2 million Danish kroner).The agreement is divided into sub-agreements (lots), where LOT-0001 (reagents for Abbott Alinity biochemistry and immunology) constitutes the absolute largest part with a maximum budgeted ceiling of 50,057,313.90 RON .(50,057,313.90 RON corresponds to approximately 75.6 million Danish kroner.) https://ted.europa.eu/en/search/result?publication-number=523285-2026&search-scope=ALL&scope=ALL&onlyLatestVersions=false&sortColumn=publication-number&sortOrder=DESC&page=1&simpleSearchRef=trueRolf Hansen We continue here on Bioporto What I meant by Bioporto being on the threshold of either a global success or a fiasco was that: When/if KDIGO finishes the mentioned documents, in my opinion, it cannot be avoided that Bioporto will achieve global success. But as long as KDIGO has not established with a finished document, where they have described in detail which treatment centers are affected by a strong recommendation and less strong recommendations, we cannot be entirely sure about the recommendations published currently. When I nevertheless wrote to you that it could also be a fiasco, it is because KDIGO has not finished rewriting the mentioned documents, and even though it seems very unlikely that they would suddenly change their mind, the risk is there until they are finished. I will compare it to what happened in Germany, that politicians for several months have publicly stated that they are working towards removing the subsidy for flower medicine, and this will only happen as of January 1, 2027. But like a thief in the night, the German parliament Bundestag decided that the subsidy should be removed as of July 30, 6 months earlier. For Stenocare's Weeco astrum 10/10, it has been an advantage, because doctors are now prescribing so many prescriptions for the oil that the pen has started to glow. In theory, the same could happen for Bioporto's NGAL test, but then it would be an inverse situation compared to Stenocare's situation. It is not normal for KDIGO to start by announcing which recommendations they will give to whom. They have made an exception this time to avoid bottleneck problems, because it is Bioporto's test they have used to come up with the recommendations below. I don't believe they will turn around on a dime and not come up with any recommendations after all, but as long as it's not set in stone, there will always be a minimal risk. But as I have written, I have bet money that there will be no negative surprises. Because during the consultation period, there was no evidence that the test did not work, only the opposite. In the same way, we also did not believe that politicians would remove the subsidy for flower medicine 6 months earlier than announced, and that it happened as described, we did not expect that to happen either. I must remember to write that the above is not a recommendation for what you should do. The red is the strongest recommendation, the blue moderate to strong recommendation, the yellow suggestion, the doctors' own assessment, the green no recommendation. https://kdigo.org/guidelines/
- ·1.8.I just discovered this from LinkedIn. I think this is relevant news because the treatment centers are in the process of complying with the various recommendations that KDIGO published in the spring. KDIGO's guideline update on biomarker use, and what the implementation actually looks like in a clinical laboratory. https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7487529288464760835&highlightedUpdateType=NETWORK_CONVERSATIONS&origin=EMAIL
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
85 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sittenGood interest in the closing auction. Wonder if they are still available for purchase tomorrow. We'll find out at 09:00. Good night and sleep well.We are slowly but surely approaching the financial report, which will be published on August 20th. There has been no news of any problems of any kind, so my expectations are that they have followed guidance to the letter. The only news I think is worth mentioning is that Bioporto has started reaching out to future customers to inform them about KDIGO's recommendations regarding the NGAL test. And we have ourselves found out that hospitals within the EU have started writing on TED that the NGAL test must meet KDIGO's recommendations when they are to have NGAL tests in their treatment system or renew a contract. They must put it out to tender every 4th year, even if they intend to keep the system they already have. EU's tender rules. I guess we will hear more about KDIGO's recommendations.
- ·3 päivää sittenInformation for the curious The summer holiday is over at BioPorto, and they have put their work clothes on again. The FDA demanded that there should be more patients, and therefore BioPorto has informed us that they need an additional 8 hospitals. Right now they have 12 hospitals. BioPorto is in full swing with the preliminary exercises to find the last 8 hospitals. I can see that, because on ClinicalTrials.gov it says 'Not yet recruiting'. If you click on information, you can see the conditions for being able to sign up for this research project. https://clinicaltrials.gov/study/NCT07751913There is soon a financial report on August 20th, it will be interesting to hear if everything goes according to plan.
- ·5.8. · MuokattuBioPorto – Presentation of H1 2026 results 20.08.2026, 14.00 tilmelding nødvendigt https://www.inderes.dk/videos/bioporto-praesentation-af-h1-2026-resultater
- ·4.8.Now the previously mentioned TED tender is over. As I have said, it is very complicated, so with good help from AI, I have arrived at the following It is Bioporto's NGAL test that the hospital in Romania has chosen. The value is 87.5 Danish kroner. the duration is over 4 years. (EU requirement that one may not enter into long-term agreements) For the sake of good order, the money will be transferred continuously. The entire agreement is stated below. The hospital has entered into a total framework agreement with a maximum framework value of 58,076,651.22 RON (corresponding to approximately 87.5 million Danish kroner).It is important to distinguish between the framework agreement's framework amount and the actual, implemented contracts: The framework agreement's maximum ceiling: The hospital can purchase for up to 58.07 million RON over the next 48 months. Implemented so far: The specific value of the contracts actually awarded and signed in this specific announcement amounts to 12,746,774.59 RON (approximately 19.2 million Danish kroner).The agreement is divided into sub-agreements (lots), where LOT-0001 (reagents for Abbott Alinity biochemistry and immunology) constitutes the absolute largest part with a maximum budgeted ceiling of 50,057,313.90 RON .(50,057,313.90 RON corresponds to approximately 75.6 million Danish kroner.) https://ted.europa.eu/en/search/result?publication-number=523285-2026&search-scope=ALL&scope=ALL&onlyLatestVersions=false&sortColumn=publication-number&sortOrder=DESC&page=1&simpleSearchRef=trueRolf Hansen We continue here on Bioporto What I meant by Bioporto being on the threshold of either a global success or a fiasco was that: When/if KDIGO finishes the mentioned documents, in my opinion, it cannot be avoided that Bioporto will achieve global success. But as long as KDIGO has not established with a finished document, where they have described in detail which treatment centers are affected by a strong recommendation and less strong recommendations, we cannot be entirely sure about the recommendations published currently. When I nevertheless wrote to you that it could also be a fiasco, it is because KDIGO has not finished rewriting the mentioned documents, and even though it seems very unlikely that they would suddenly change their mind, the risk is there until they are finished. I will compare it to what happened in Germany, that politicians for several months have publicly stated that they are working towards removing the subsidy for flower medicine, and this will only happen as of January 1, 2027. But like a thief in the night, the German parliament Bundestag decided that the subsidy should be removed as of July 30, 6 months earlier. For Stenocare's Weeco astrum 10/10, it has been an advantage, because doctors are now prescribing so many prescriptions for the oil that the pen has started to glow. In theory, the same could happen for Bioporto's NGAL test, but then it would be an inverse situation compared to Stenocare's situation. It is not normal for KDIGO to start by announcing which recommendations they will give to whom. They have made an exception this time to avoid bottleneck problems, because it is Bioporto's test they have used to come up with the recommendations below. I don't believe they will turn around on a dime and not come up with any recommendations after all, but as long as it's not set in stone, there will always be a minimal risk. But as I have written, I have bet money that there will be no negative surprises. Because during the consultation period, there was no evidence that the test did not work, only the opposite. In the same way, we also did not believe that politicians would remove the subsidy for flower medicine 6 months earlier than announced, and that it happened as described, we did not expect that to happen either. I must remember to write that the above is not a recommendation for what you should do. The red is the strongest recommendation, the blue moderate to strong recommendation, the yellow suggestion, the doctors' own assessment, the green no recommendation. https://kdigo.org/guidelines/
- ·1.8.I just discovered this from LinkedIn. I think this is relevant news because the treatment centers are in the process of complying with the various recommendations that KDIGO published in the spring. KDIGO's guideline update on biomarker use, and what the implementation actually looks like in a clinical laboratory. https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7487529288464760835&highlightedUpdateType=NETWORK_CONVERSATIONS&origin=EMAIL
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt